Novira Therapeutics is a company.
Novira Therapeutics has raised $25.0M across 1 funding round.
Key people at Novira Therapeutics.
Novira Therapeutics has raised $25.0M in total across 1 funding round.
Novira Therapeutics was a clinical-stage biopharmaceutical company developing first-in-class oral antiviral therapies targeting the viral capsid for chronic hepatitis B (CHB) and HIV infections, addressing major global unmet needs in infectious diseases.[1][2] It served patients with these chronic viral infections, aiming to provide novel monotherapies or combinations superior to existing standards of care, with a focus on HBV as a primary indication.[1][2]
The company demonstrated early promise in drug discovery but was ultimately acquired by Johnson & Johnson in 2016, integrating its pipeline into Janssen's Infectious Diseases & Vaccines unit, which accelerated development amid J&J's push for innovative therapies like Darzalex.[3][4]
Novira Therapeutics emerged from Versant Ventures' portfolio, backed by investors including Johnson & Johnson Innovation, with a founding focus on novel antivirals for HBV and HIV.[1][2] Key leadership included experienced executives like Schade, previously at Medarex (acquired by Bristol-Myers Squibb), bringing expertise in antibody therapeutics, oncology, and infectious diseases from roles at Merrill Lynch and JP Morgan.[2]
The idea stemmed from targeting the viral capsid—a underexplored mechanism for oral drugs—gaining traction through preclinical advancements that positioned it for acquisition by J&J's Janssen in 2016, amid J&J's strategy of bolt-on deals to bolster its pipeline against patent cliffs on blockbusters like Remicade.[3][4]
Novira rode the wave of structure-based drug design in antivirals, capitalizing on HBV's 250+ million chronic carriers worldwide and the push beyond suppressive therapies toward functional cures.[1][2] Timing aligned with 2010s biotech M&A surge, as big pharma like J&J addressed pipeline gaps from patent expirations (e.g., Remicade biosimilars) via acquisitions like Novira, alongside Alios BioPharma and others.[3][4]
It influenced the ecosystem by validating capsid inhibitors as a viable class—now pursued by peers—while amplifying J&J's infectious disease portfolio, contributing to goals like 10 novel blockbuster therapies by decade's end.[3]
Post-acquisition, Novira's assets advanced within Janssen, potentially yielding HBV candidates amid rising demand for curative antivirals amid evolving standards like siRNA combos. Trends like AI-driven protein modeling and combo regimens will shape progress, with J&J's scale positioning remnants for Phase II/III milestones or partnerships.[3][4]
Its legacy underscores nimble biotech's role in feeding pharma pipelines, evolving from standalone innovator to integrated powerhouse in the fight against viral pandemics.
Novira Therapeutics has raised $25.0M in total across 1 funding round.
Novira Therapeutics's investors include 5AM Ventures, Canaan Partners, Venrock.
Key people at Novira Therapeutics.
Novira Therapeutics has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $25.0M Series A | 5AM Ventures, Canaan Partners, Venrock |
